Nanoparticle Manufacturing

Chapter Outlines

Chapter 2 is an executive summary of key insights captured during our research. It offers a high-level view on the likely evolution of the nanoparticle contract manufacturing market in the short to mid-term, and long term.

Chapter 3 provides a general introduction on nanoparticles, along with information on various types and applications of nanoparticles in the pharmaceutical industry. Additionally, it includes information on the various challenges associated with manufacturing of nanoparticles. Further, it features a brief discussion on the growing need for outsourcing within this domain.

Chapter 4 provides a detailed review of the overall landscape of nanoparticle contract manufacturing landscape. It includes information of over 50 contract manufacturers currently engaged in the domain of nanoparticle contract manufacturing. Additionally, it features an in-depth analysis of service providers, based on several relevant parameters, such as year of establishment, company size (very small, small, mid-sized and large), location of headquarters (region-wise), type of organization (CDMO and CMO), type of nanoparticle(s) manufactured (lipid and metal nanoparticles), location and number of nanoparticle manufacturing facilities, scale of operation (preclinical, clinical and commercial), type of end user (educational institutions, pharmaceutical companies, research institutions and other end users), quality certifications, regulatory organizations and include details on type of services offered (analytical method development, fill / finish and packaging, formulation development, manufacturing, method qualification and sustainability, process development / pre-formulation, scale-up, stability studies, and other services).

Chapter 5 highlights the contemporary market trends in six schematic representations, which include [A] a bubble representation based on company size and type of organization, [B] a comparative world map representation, based on company size, location of the headquarters and type of nanoparticle(s) manufactured, [C] a stacked bar chart representation based on company size and scale of operation, [D] a heat map representation highlighting the regional distribution of developers engaged in this domain,  [E] a 4D bubble analysis comparing the leading players engaged in this domain, based on several relevant parameters (such as company size, type of nanoparticle(s) manufactured, number of manufacturing facilities, and number of services offered,), [F] a grid representation illustrating the distribution of nanoparticle contract manufacturers based several relevant parameters (such as type of organization, type of nanoparticle(s) manufactured, scale of operation, type of end user, and types of service(s) offered).

Chapter 6 features a detailed company competitiveness analysis of the nanoparticle contract manufacturers, of very small, small, mid-sized and large companies, based on several relevant parameters, such as company’s service strength (taking into consideration a number of parameters, such as years of experience, type of organization, type of nanoparticle(s) manufactured, number of manufacturing facilities, scale of operation, type of end user and  types of service(s) offered) and partnership strength (taking into consideration the number of partnerships and type of agreement).

Chapter 7 provides detailed profiles of the key players (shortlisted based on a proprietary criterion) that are active in the nanoparticle contract manufacturing market. Each profile provides an overview of the company, along with information on year of establishment, location of headquarters, number of employees, key executives, details on recent developments, as well as an informed future outlook.

Chapter 8 features an analysis of recent collaborations and partnerships that have been inked between several stakeholders engaged in this domain, during the period 2015-2021. It includes a brief description of the partnership models (including company acquisitions, manufacturing agreements, mergers, product development agreements, product distribution agreements, technology integration agreements, and other agreements) adopted by various stakeholders in the domain of nanoparticle contract manufacturing. Further, it comprises of analysis based on the year of partnership, type of partner, type of nanoparticle(s) manufactured, emerging focus area, seniority level of stakeholders, most active players (in terms of number of partnerships), type of agreement. Further, the chapter includes a world map representation of all the deals inked in this field in the period 2015-2021, highlighting both intercontinental and intracontinental partnership activity.

Chapter 9 presents an insightful analysis that highlights the various factors that need to be taken into consideration by nanoparticle-based therapeutics developers, while deciding whether to manufacture their respective therapeutics in-house or engage the services of a CMOs. Further, the analysis highlights all the key parameters that must be considered by players of different company sizes (very small, small, mid-sized, and large) while taking the aforementioned decision.

Chapter 10 features a comprehensive market forecast analysis, highlighting the likely growth of the nanoparticle contract manufacturing market, for the period 2021-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] company size (very small, small mid-sized, and large), [B] type of nanoparticle(s) manufactured (lipid and metal nanoparticles), [C] scale of operation (preclinical, clinical and commercial) and [D] type of end user (educational institutions, pharmaceutical companies, research institutions, and other end users), and [E] key geographical regions (North America, Europe, Asia, MENA, Latin America and rest of the world).

Chapter 11 is a summary of the entire report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 12 provides the transcripts of interviews conducted with representatives from renowned organizations, which are engaged in the domain of nanoparticle contract manufacturing. In this chapter, we have presented the details of our conversation with Asha Van Rooijen and Bart Metselaar (Founder and Chief Executive Officer, Director, Research and Development, LIPOSOMA).

Chapter 13 is an appendix, that provides tabulated data and numbers for all the figures included in the report.

Chapter 14 is an appendix that provides the list of companies and organizations that have been mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Nanoparticles
3.2.1. Type of Nanoparticles

3.3. Challenges Associated with Manufacturing of Nanoparticles 
3.4 Overview of Contract Manufacturing
3.4.1 Commonly Outsourced Nanoparticle Manufacturing Operations

3.5. Advantages of Outsourcing Nanoparticle Manufacturing Operations
3.6. Key Considerations while Selecting a Contract Manufacturing Partner
3.7. Future Perspective

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Nanoparticle Contract Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Type of Organization 
4.2.5. Analysis by Type of Nanoparticle(s) Manufactured
4.2.6. Analysis by Location of Manufacturing Facilities
4.2.7. Analysis by Scale of Operation
4.2.8. Analysis by Type of End User
4.2.9. Analysis by Type of Service(s) Offered
4.2.10. Analysis by Quality Certifications
4.2.11. Analysis by Regulatory Organizations
4.2.12. Leading Nanoparticle Contract Manufacturers: Analysis by Number of Manufacturing Facilities

5. KEY INSIGHTS
5.1. Chapter Overview
5.2. Analysis by Company Size and Type of Organization
5.3. Analysis by Company Size and Type of Nanoparticle(s) Manufactured
5.4. Analysis by Company Size and Scale of Operation
5.5. Analysis by Location of Headquarters (Country-wise)
5.6. Analysis by Company Size, Type of Nanoparticle(s) Manufactured, Number of Manufacturing Facilities, and Number of Services Offered (4D Bubble Representation)
5.7. Analysis by Type of Organization, Type of Nanoparticle(s) Manufactured, Scale of Operation, Type of End User, Type of Service(s) Offered (Grid Representation)

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Assumptions and Key Parameters
6.3. Methodology
6.4. Benchmarking of Service Strength
6.5. Benchmarking of Partnership Activity
6.6. Nanoparticle Contract Manufacturers: Company Competitiveness Analysis
6.6.1. Company Competitiveness Analysis: Very Small Companies
6.6.2. Company Competitiveness Analysis: Small Companies
6.6.3. Company Competitiveness Analysis: Mid-Sized Companies
6.6.4. Company Competitiveness Analysis: Large Companies

7. COMPANY PROFILES
7.1. Chapter Overview
7.2. Ardena
7.2.1. Company Overview
7.2.2. Recent Developments and Future Outlook

7.3. CordenPharma 
7.3.1. Company Overview
7.3.2. Recent Developments and Future Outlook

7.4. Curia 
7.4.1. Company Overview
7.4.2. Recent Developments and Future Outlook

7.5. Evonik 
7.5.1. Company Overview
7.5.2. Recent Developments and Future Outlook

7.6. LSNE Contract Manufacturing
7.6.1. Company Overview
7.6.2. Recent Developments and Future Outlook

7.7. Polymun
7.7.1. Company Overview
7.7.2. Recent Developments and Future Outlook

7.8. TechNanoIndia
7.8.1. Company Overview
7.8.2. Recent Developments and Future Outlook

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Nanoparticle Contract Manufacturing: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Type of Partner 
8.3.4. Analysis by Type of Nanoparticle(s) Manufactured
8.3.5. Emerging Focus Areas
8.3.6. Most Active Players: Analysis by Number of Partnerships
8.3.7. Analysis by Geography
8.3.7.1. Region-wise Distribution
8.3.7.2. Country-wise Distribution

8.8. Concluding Remarks

9. OUTSOURCING: GO / NO-GO FRAMEWORK
9.1. Chapter Overview
9.2. Outsourcing: Go / No-Go Framework 
9.3. Nanoparticle-based Therapeutics Developers Outsourcing: Go / No-Go Framework
9.3.1. Assumptions and Parameter Definitions
9.3.2. Methodology
9.3.3. Results and Interpretations
9.3.3.1. Very Small Companies
9. 3.3.2. Small Companies
9. 3.3.3. Mid-Sized Companies
9. 3.3.4. Large Companies
9. 3.3.4. Very Large Companies

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Global Nanoparticle Contract Manufacturing Market, 2021-2035
10.4. Nanoparticle Contract Manufacturing Market: Distribution by Company Size, 2021 and 2035
10.4.1. Nanoparticle Contract Manufacturing Market for Very Small Companies, 2021-2035
10.4.2. Nanoparticle Contract Manufacturing Market for Small Companies, 2021-2035 
10.4.3. Nanoparticle Contract Manufacturing Market for Mid-Sized Companies, 2021-2035
10.4.4. Nanoparticle Contract Manufacturing Market for Large Companies, 2021-2035 

10.5. Nanoparticle Contract Manufacturing Market: Distribution by Type of Nanoparticle(s) Manufactured, 2021 and 2035
10.5.1. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles, 2021-2035 
10.5.2. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles, 2021-2035

10.6. Nanoparticle Contract Manufacturing Market: Distribution by Scale of Operation, 2021 and 2035
10.6.1. Nanoparticle Contract Manufacturing Market for Preclinical Scale Operations, 2021-2035 
10.6.2. Nanoparticle Contract Manufacturing Market for Clinical Scale Operations, 2021-2035 
10.6.3. Nanoparticle Contract Manufacturing Market for Commercial Scale Operations, 2021-2035 

10.7. Nanoparticle Contract Manufacturing Market: Distribution by Type of End User, 2021 and 2035
10.7.1. Nanoparticle Contract Manufacturing Market for Educational Institutions, 2021-2035
10.7.2. Nanoparticle Contract Manufacturing Market for Pharmaceutical Companies, 2021-2035 
10.7.3. Nanoparticle Contract Manufacturing Market for Research Institutions, 2021-2035
10.7.4. Nanoparticle Contract Manufacturing Market for Other End Users, 2021-2035 

10.8. Nanoparticle Contract Manufacturing Market: Distribution by Region, 2021 and 2035
10.8.1. Nanoparticle Contract Manufacturing Market in North America, 2021-2035
10.8.2. Nanoparticle Contract Manufacturing Market in Europe, 2021-2035
10.8.3. Nanoparticle Contract Manufacturing Market in Asia, 2021-2035
10.8.4. Nanoparticle Contract Manufacturing Market in MENA, 2021-2035
10.8.5. Nanoparticle Contract Manufacturing Market in Latin America, 2021-2035
10.8.6. Nanoparticle Contract Manufacturing Market in Rest of the World, 2021-2035

10.9. Nanoparticle Contract Manufacturing Market: Distribution by Type of Nanoparticle and Region, 2021 and 2035
10.9.1. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in North America, 2021-2035
10.9.2. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Europe, 2021-2035
10.9.3. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Asia, 2021-2035
10.9.4. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in MENA, 2021-2035
10.9.5. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Latin America, 2021-2035
10.9.6. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Rest of the World, 2021-2035
10.9.7. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in North America, 2021-2035
10.9.8. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Europe, 2021-2035
10.9.9. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Asia, 2021-2035
10.9.10. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in MENA, 2021-2035
10.9.11. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Latin America, 2021-2035
10.9.12. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Rest of the World, 2021-2035

10.10. Concluding Remarks

11. CONCLUDING REMARKS
11.1. Chapter Overview

12. EXECUTIVE INSIGHTS
12.1. Chapter Overview
12.2. LIPOSOMA
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Asha Van Rooijen, Founder and Chief Executive Officer, Bart Metselaar, Director, Research and Development

13. APPENDIX I: TABULATED DATA

14. APPENDIX II: LIST OF COMPANIES AND ORGANIZATION

List Of Figures

Figure 2.1 Executive Summary: Market Landscape
Figure 2.2 Executive Summary: Partnerships and Collaborations
Figure 2.3 Executive Summary: Market Forecast
Figure 3.1 Application of Nanoparticles in Healthcare
Figure 3.2 Type of Nanoparticles: Based on Source of Material
Figure 3.3 Challenges Associated with Manufacturing of Nanoparticles
Figure 3.4 Type of the Third- Party Service Providers
Figure 3.5 Commonly Outsourced Nanoparticle Manufacturing Operations
Figure 4.1 Nanoparticle Contract Manufactures: Distribution by Year of Establishment
Figure 4.2 Nanoparticle Contract Manufactures: Distribution by Company Size
Figure 4.3 Nanoparticle Contract Manufactures: Distribution by Location of Headquarters
Figure 4.4 Nanoparticle Contract Manufactures: Distribution by Company Size and Location of Headquarters
Figure 4.5 Nanoparticle Contract Manufactures: Distribution by Type of Organization
Figure 4.6 Nanoparticle Contract Manufactures: Distribution by Type of Nanoparticle(s) Manufactured
Figure 4.7 Nanoparticle Contract Manufactures: Distribution by Location of Headquarters and Type of Nanoparticle(s) Manufactured
Figure 4.8 Nanoparticle Contract Manufactures: Distribution by Type of Organization and Type of Nanoparticle(s) Manufactured
Figure 4.9 Nanoparticle Contract Manufactures: Distribution by Location of Manufacturing Facility
Figure 4.10 Nanoparticle Contract Manufactures: Distribution by Location of Manufacturing Facility (Country-wise)
Figure 4.11 Nanoparticle Contract Manufactures: Distribution by Scale of Operation
Figure 4.12 Nanoparticle Contract Manufactures: Distribution by Type of Organization and Scale of Operation
Figure 4.13 Nanoparticle Contract Manufactures: Distribution by Type of Nanoparticle(s) Manufactured and Scale of Operation
Figure 4.14 Nanoparticle Contract Manufactures: Distribution by Type of End User
Figure 4.15 Nanoparticle Contract Manufactures: Distribution by Type of Nanoparticle(s) Manufactured and Type of End User
Figure 4.16 Nanoparticle Contract Manufactures: Distribution by Type of Service(s) Offered
Figure 4.17 Nanoparticle Contract Manufactures: Distribution by Type of Organization and Type of End User
Figure 4.18 Nanoparticle Contract Manufactures: Distribution by Type of Nanoparticle(s) Manufactured and Type of Service(s) Offered
Figure 4.19 Nanoparticle Contract Manufactures: Distribution by Quality Certifications
Figure 4.20 Nanoparticle Contract Manufactures: Distribution by Regulatory Bodies
Figure 4.21 Leading Nanoparticle Contract Manufacturers: Distribution by Number of Manufacturing Facilities
Figure 5.1 Key Insights: Distribution by Company Size and Type of Organization
Figure 5.2 Key Insights: Distribution by Company Size and Type of Nanoparticle(s) Manufactured
Figure 5.3 Key Insights: Distribution by Company Size and Scale of Operation
Figure 5.4 Key Insights: Distribution by Location of Headquarters (Country-wise)
Figure 5.5 4D Bubble Representation: Distribution by Number of Manufacturing Facilities, Number of Service(s) Offered, Company Size, and Type of Nanoparticle(s) Manufactured 
Figure 5.6 Grid Representation: Distribution by Type of Organization, Type of Nanoparticle(s) Manufactured, Scale of Operation, Type of End User, and Type of Service(s) Offered
Figure 6.1 Nanoparticle Contract Manufacturers: Benchmarking of Service Strength
Figure 6.2 Nanoparticle Contract Manufacturers: Benchmarking of Partnership Activity
Figure 6.3 Company Competitiveness Analysis: Very Small Companies
Figure 6.4 Company Competitiveness Analysis: Small Companies
Figure 6.5 Company Competitiveness Analysis: Mid-sized Companies
Figure 6.6 Company Competitiveness Analysis: Large Companies
Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2021
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Year-wise Cumulative Distribution by Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 8.5 Partnerships and Collaborations: Year-wise Distribution by Type of Partner
Figure 8.6 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 8.7 Partnerships and Collaborations: Distribution by Type of Partner and Company Size
Figure 8.8 Partnerships and Collaborations: Distribution by Type of Partner, Company Size and Location of Headquarters
Figure 8.9 Partnerships and Collaborations: Distribution by Type of Nanoparticle(s) Manufactured
Figure 8.10 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Nanoparticle(s) Manufactured
Figure 8.11 Partnerships and Collaborations: Distribution by Location of Partner and Type of Nanoparticle(s) Manufactured
Figure 8.12 Partnerships and Collaborations: Emerging Focus Area
Figure 8.13 Most Active Players: Distribution by Number of Partnerships
Figure 8.14 Partnerships and Collaboration: Region-wise Distribution
Figure 8.15 Partnerships and Collaborations: Country-wise Distribution
Figure 8.15 Partnerships and Collaboration: Concluding Remarks
Figure 9.1 Outsourcing: Go / No-Go Framework
Figure 9.2 Outsourcing: Go / No-Go Framework Methodology
Figure 9.3 Outsourcing: Go / No-Go Framework for Nanoparticle-based Therapeutic Developers
Figure 9.4 Nanoparticle-based Therapeutic Developers: Benchmarking of Very Small Companies
Figure 9.5 Nanoparticle-based Therapeutic Developers: Benchmarking of Small Companies
Figure 9.6 Nanoparticle-based Therapeutic Developers: Benchmarking of Mid-sized Companies
Figure 9.7 Nanoparticle-based Therapeutic Developers: Benchmarking of Large Companies
Figure 9.8 Nanoparticle-based Therapeutic Developers: Benchmarking of Very Large Companies
Figure 10.1 Global Nanoparticle Contract Manufacturing Market, 2021-2035 (USD Million)
Figure 10.2 Nanoparticle Contract Manufacturing Market: Distribution by Company Size, 2021 and 2035
Figure 10.3 Nanoparticle Contract Manufacturing Market for Very Small Companies, 2021-2035 (USD Million)
Figure 10.4 Nanoparticle Contract Manufacturing Market for Small Companies, 2021-2035 (USD Million)
Figure 10.5 Nanoparticle Contract Manufacturing Market for Mid-Sized Companies, 2021-2035 (USD Million)
Figure 10.6 Nanoparticle Contract Manufacturing Market for Large Companies, 2021-2035 (USD Million)
Figure 10.7 Nanoparticle Contract Manufacturing Market: Distribution by Type of Nanoparticle(s) Manufactured, 2021 and 2035
Figure 10.8 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles, 2021-2035 (USD Million)
Figure 10.9 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles, 2021-2035 (USD Million)
Figure 10.10 Nanoparticle Contract Manufacturing Market: Distribution by Scale of Operation, 2021 and 2035
Figure 10.11 Nanoparticle Contract Manufacturing Market for Preclinical Scale Operations, 2021-2035 (USD Million)
Figure 10.12 Nanoparticle Contract Manufacturing Market for Clinical Scale Operations, 2021-2035 (USD Million)
Figure 10.13 Nanoparticle Contract Manufacturing Market for Commercial Scale Operations, 2021-2035 (USD Million)
Figure 10.14 Nanoparticle Contract Manufacturing Market: Distribution by Type of End User, 2021 and 2035
Figure 10.15 Nanoparticle Contract Manufacturing Market for Educational Institutions, 2021-2035 (USD Million)
Figure 10.16 Nanoparticle Contract Manufacturing Market for Pharmaceutical Companies, 2021-2035 (USD Million)
Figure 10.17 Nanoparticle Contract Manufacturing Market for Research Institutions, 2021-2035 (USD Million)
Figure 10.18 Nanoparticle Contract Manufacturing Market for Other End Users, 2021-2035 (USD Million)
Figure 10.19 Nanoparticle Contract Manufacturing Market: Distribution by Region, 2021 and 2035
Figure 10.20 Nanoparticle Contract Manufacturing Market in North America, 2021-2035 (USD Million)
Figure 10.21 Nanoparticle Contract Manufacturing Market in Europe, 2021-2035 (USD Million)
Figure 10.22 Nanoparticle Contract Manufacturing Market in Asia, 2021-2035 (USD Million)
Figure 10.23 Nanoparticle Contract Manufacturing Market in MENA, 2021-2035 (USD Million)
Figure 10.24 Nanoparticle Contract Manufacturing Market in Latin America, 2021-2035 (USD Million)
Figure 10.25 Nanoparticle Contract Manufacturing Market in Rest of the World, 2021-2035 (USD Million)
Figure 10.26 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in North America, 2021-2035 (USD Million)
Figure 10.27 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Europe, 2021-2035 (USD Million)
Figure 10.28 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Asia, 2021-2035 (USD Million)
Figure 10.29 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in MENA, 2021-2035 (USD Million)
Figure 10.30 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Latin America, 2021-2035 (USD Million)
Figure 10.31 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Rest of the World, 2021-2035 (USD Million)
Figure 10.32 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in North America, 2021-2035 (USD Million)
Figure 10.33 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Europe, 2021-2035 (USD Million)
Figure 10.34 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Asia, 2021-2035 (USD Million)
Figure 10.35 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in MENA, 2021-2035 (USD Million)
Figure 10.36 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Latin America, 2021-2035 (USD Million)
Figure 10.37 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Rest of the World, 2021-2035 (USD Million)
Figure 10.38 Nanoparticle Contract Manufacturing Market, Conservative, Base and Optimistic Scenarios, 2021, 2028 and 2035 (USD Million)
Figure 11.1 Concluding Remarks: Current Market Landscape
Figure 11.2 Concluding Remarks: Key Insights
Figure 11.3 Concluding Remarks: Company Competitiveness Analysis: Small Companies
Figure 11.4 Concluding Remarks: Partnerships and Collaborations
Figure 11.5 Concluding Remarks: Outsourcing: Go / No-Go Framework
Figure 11.6 Concluding Remarks: Market Sizing and Opportunity Analysis
Figure 11.7 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 4.1 Nanoparticle Contract Manufacturers: List of Companies
Table 4.2 Nanoparticle Contract Manufacturers: Information on Type of Organization and Type of Nanoparticle(s) Manufactured
Table 4.3 Nanoparticle Contract Manufacturers: Information on Location of Manufacturing Facility
Table 4.4 Nanoparticle Contract Manufacturers: Information on Scale of Operation
Table 4.5 Nanoparticle Contract Manufacturers: Information on Type of End User
Table 4.6 Nanoparticle Contract Manufacturers: Information on Type of Service(s) Offered
Table 4.7 Nanoparticle Contract Manufacturers: Information on Quality Certifications and Regulatory Bodies
Table 6.1 Company Competitiveness Analysis: Benchmarking of Service Strength
Table 6.2 Company Competitiveness Analysis: Benchmarking of Partnership Strength
Table 6.3 Company Competitiveness Analysis: List of Very Small Players
Table 6.3 Company Competitiveness Analysis: List of Small Players
Table 6.3 Company Competitiveness Analysis: List of Mid-Sized Players
Table 6.3 Company Competitiveness Analysis: List of Large Players
Table 7.1 Nanoparticle Contract Manufacturers: List of Companies Profiled
Table 7.2 Ardena: Company Snapshot
Table 7.3 Ardena: Recent Developments and Future Outlook
Table 7.4 CordenPharma: Company Snapshot
Table 7.5 CordenPharma: Recent Developments and Future Outlook
Table 7.6 Curia: Company Snapshot
Table 7.7 Curia: Recent Developments and Future Outlook
Table 7.8 Evonik: Company Snapshot
Table 7.9 Evonik: Recent Developments and Future Outlook
Table 7.10 LSNE Contract Manufacturing: Company Snapshot
Table 7.11 LSNE Contract Manufacturing: Recent Developments and Future Outlook
Table 7.12 Polymun: Company Snapshot
Table 7.13 Polymun: Recent Developments and Future Outlook
Table 7.14 TeachNanoIndia: Company Snapshot
Table 8.1 Nanoparticle Contract Manufacturers: List of Collaborations, 2015-2021
Table 8.2 Nanoparticle Contract Manufacturers: Partnerships and Collaborations, Information on Type of Agreement (Region-wise and Geography-wise) and Designation of Stakeholder
Table 12.1: LIPOSOMA: Company Snapshot
Table 13.1 Nanoparticle Contract Manufactures: Cumulative Distribution by Year of Establishment
Table 13.2 Nanoparticle Contract Manufactures: Distribution by Company Size
Table 13.3 Nanoparticle Contract Manufactures: Distribution by Location of Headquarters
Table 13.4 Nanoparticle Contract Manufactures: Distribution by Company Size and Location of Headquarters
Table 13.5 Nanoparticle Contract Manufactures: Distribution by Type of Organization
Table 13.6 Nanoparticle Contract Manufactures: Distribution by Type of Nanoparticle(s) Manufactured
Table 13.7 Nanoparticle Contract Manufactures: Distribution by Location of Headquarters and Type of Nanoparticle(s) Manufactured
Table 13.8 Nanoparticle Contract Manufactures: Distribution by Type of Organization and Type of Nanoparticle(s) Manufactured
Table 13.9 Nanoparticle Contract Manufactures: Distribution by Location of Manufacturing Facility
Table 13.10 Nanoparticle Contract Manufactures: Distribution by Location of Manufacturing Facility (Country-wise)
Table 13.11 Nanoparticle Contract Manufactures: Distribution by Scale of Operation
Table 13.12 Nanoparticle Contract Manufactures: Distribution by Type of Organization and Scale of Operation
Table 13.13 Nanoparticle Contract Manufactures: Distribution by Type of Nanoparticle(s) Manufactured and Scale of Operation
Table 13.14 Nanoparticle Contract Manufactures: Distribution by Type of End User
Table 13.15 Nanoparticle Contract Manufactures: Distribution by Type of Nanoparticle(s) Manufactured and Type of End User
Table 13.16 Nanoparticle Contract Manufactures: Distribution by Type of Service(s) Offered
Table 13.17 Nanoparticle Contract Manufactures: Distribution by Type of Organization and Type of End User
Table 13.18 Nanoparticle Contract Manufactures: Distribution by Type of Nanoparticle(s) Manufactured and Type of Service(s) Offered
Table 13.19 Nanoparticle Contract Manufactures: Distribution by Quality Certifications
Table 13.20 Nanoparticle Contract Manufactures: Distribution by Regulatory Bodies
Table 13.21 Leading Nanoparticle Contract Manufacturers: Distribution by Number of Manufacturing Facilities
Table 13.22 Key Insights: Distribution by Company Size and Type of Organization
Table 13.23 Key Insights: Distribution by Company Size and Type of Nanoparticle(s) Manufactured
Table 13.24 Key Insights: Distribution by Company Size and Scale of Operation
Table 13.25 Key Insights: Distribution by Location of Headquarters (Country-wise)
Table 13.26 4D Bubble Representation: Distribution by Number of Manufacturing Facilities, Number of Services Offered, Company Size, and Type of Nanoparticle(s) Manufactured, 
Table 13.27 Grid Representation: Distribution by Type of Organization, Type of Nanoparticle(s) Manufactured, Scale of Operation, Type of End User, and Type of Service(s) Offered
Table 13.28 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2021
Table 13.29 Partnerships and Collaborations: Distribution by Type of Partnership
Table 13.30 Partnerships and Collaborations: Cumulative Year-wise Trend by Type of Partnership
Table 13.31 Partnerships and Collaborations: Distribution by Type of Partner
Table 13.32 Partnerships and Collaborations: Year-wise Distribution by Type of Partner
Table 13.33 Partnerships and Collaborations: Cumulative Distribution by Type of Partnership and Type of Partner
Table 13.34 Partnerships and Collaborations: Type of Partner and Company Size
Table 13.35 Partnerships and Collaborations: Distribution by Type of Partner, Company Size and Location of Headquarters
Table 13.36 Partnerships and Collaborations: Distribution by Type of Nanoparticle(s) Manufactured
Table 13.37 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Nanoparticle(s) Manufactured
Table 13.38 Partnerships and Collaborations: Partnerships and Collaborations: Distribution by Location of Partner and Type of Nanoparticle(s) Manufactured
Table 13.39 Most Active Players: Distribution by Number of Partnerships
Table 13.40 Partnerships and Collaborations: Region-wise Distribution
Table 13.41 Partnerships and Collaborations: Country-wise Distribution
Table 13.42 Partnerships and Collaborations: Concluding Remarks
Table 13.43 Global Nanoparticle Contract Manufacturing Market, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Million)
Table 13.44 Nanoparticle Contract Manufacturing Market: Distribution by Company Size, 2021 and 2035
Table 13.45 Nanoparticle Contract Manufacturing Market for Very Small Companies, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Million)
Table 13.46 Nanoparticle Contract Manufacturing Market for Small Companies, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Million)
Table 13.47 Nanoparticle Contract Manufacturing Market for Mid-Sized Companies, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Million)
Table 13.48 Nanoparticle Contract Manufacturing Market for Large Companies, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Million)
Table 13.49 Nanoparticle Contract Manufacturing Market: Distribution by Type of Nanoparticle(s) Manufactured, 2021 and 2035
Table 13.50 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Million)
Table 13.51 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Million)
Table 13.52 Nanoparticle Contract Manufacturing Market: Distribution by Scale of Operation, 2021 and 2035
Table 13.53 Nanoparticle Contract Manufacturing Market for Preclinical Scale Operations, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Million)
Table 13.54 Nanoparticle Contract Manufacturing Market for Clinical Scale Operations, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Million)
Table 13.55 Nanoparticle Contract Manufacturing Market for Commercial Scale Operations, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Million)
Table 13.56 Nanoparticle Contract Manufacturing Market: Distribution by Type of End User, 2021 and 2035
Table 13.57 Nanoparticle Contract Manufacturing Market for Educational Institutions, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Million)
Table 13.58 Nanoparticle Contract Manufacturing Market for Pharmaceutical Companies, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Million)
Table 13.59 Nanoparticle Contract Manufacturing Market for Research Institutions, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Million)
Table 13.60 Nanoparticle Contract Manufacturing Market for Other End Users, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Million)
Table 13.61 Nanoparticle Contract Manufacturing Market: Distribution by Region, 2021 and 2035
Table 13.62 Nanoparticle Contract Manufacturing Market in North America, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Million)
Table 13.63 Nanoparticle Contract Manufacturing Market in Europe, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Million)
Table 13.64 Nanoparticle Contract Manufacturing Market in Asia, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Million)
Table 13.65 Nanoparticle Contract Manufacturing Market in MENA, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Million)
Table 13.66 Nanoparticle Contract Manufacturing Market in Latin America, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Million)
Table 13.67 Nanoparticle Contract Manufacturing Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Million)
Table 13.68 Nanoparticle Contract Manufacturing Market: Distribution by Type of Nanoparticle(s) Manufactured and Region, 2021 and 2035
Table 13.69 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in North America, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Million)
Table 13.70 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Europe, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Million)
Table 13.71 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Asia, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Million)
Table 13.72 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in MENA, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Million)
Table 13.73 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Latin America, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Million)
Table 13.74 Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Rest of the World, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Million)
Table 13.75 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in North America, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Million)
Table 13.76 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Europe, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Million)
Table 13.77 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Asia, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Million)
Table 13.78 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in MENA, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Million)
Table 13.79 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Latin America, Conservative, Base and Optimistic Scenarios, 2021-2035 (USD Million)
Table 13.80 Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Rest of the World, 2021-2035 (USD Million)
Table 13.81 Nanoparticle Contract Manufacturing Market, Conservative, Base and Optimistic Scenarios, 2021, 2028 and 2035 (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report. 

1. Ajinomoto Bio-Pharma Services
2. Alfa Aesar
3. Amplicon Biotech
4. Applied Chemical Works
5. Arcturus Therapeutics
6. Ardena
7. Ascendia Pharmaceuticals
8. AstraZeneca
9. AVANSA Technology & Services
10. Avanti Polar Lipids
11. Axolabs
12. BASF
13. BBI Group
14. BioNTech
15. BIOZOL Diagnostica
16. BOC Sciences
17. Caisson Biotech
18. Cal Nano
19. Cambridge Nanomaterials Technology
20. CanSinoBIO
21. Cayman Chemical
22. CONTRACTOR BUSINESS CENTER
23. Celonic
24. Center for Applied Nanotechnology
25. Cerion
26. ChemConnection 
27. CliniSciences
28. CordenPharma
29. Creative Biolabs
30. Croda
31. Crystallics
32. CureVac
33. Curia
34. CYBERNANO
35. Cytodiagnostics 
36. Daiichi Sankyo
37. Danaher
38. DCN Dx
39. Deakin University
40. Dolomite Microfluidics
41. E.M. Sullivan Associates
42. Eikonix
43. EMJapan
44. Encapsula NanoSciences
45. Entos
46. European Commission
47. Evonik
48. Exelead
49. Fortis Life Sciences
50. FUJIFILM Holdings 
51. GHO Capital
52. Howei Pharm
53. Hongwu International Group
54. i-DNA Biotechnology
55. Idifarma
56. Integrity Bio
57. Larodan
58. LEON
59. LIPOSOMA
60. LSNE Contract Manufacturing
61. Meliorum Technologies
62. Molchem Technologies UK
63. MyBiotech
64. Nagase Medicals
65. Nanochemazone
66. nanoComposix
67. Nanocs
68. NanoHybrids
69. NanoMaterials Technology
70. Nanomics Technologies 
71. Nanophase Technologies
72. Nanoshel
73. Nanostructured & Amorphous Materials
74. NARD Institute
75. NNCrystal
76. Novo Holdings
77. Nucleus Medical Media
78. NVIGEN
79. NYACOL® Nano Technologies
80. Ocean NanoTech
81. Osaka University
82. Permira
83. Pfizer
84. Pharmavize
85. Phosphorex
86. Polymun
87. Precision NanoSystems
88. Pró-Análise 
89. Prodotti Gianni
90. Santhiram Chemicals
91. Seashell Technology
92. Shionogi
93. Sirnaomics
94. SkySpring Nanomaterials
95. Stanipharm
96. Stratech Scientific
97. Strem 
98. Syntagon
99. T&T Scientific
100. TechNanoIndia
101. The Energy and Resources Institute (TERI)
102. U.S. Army
103. Vaxinano
104. Veritas Technologies
105. ZoneOne Pharma